X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4) 4
index medicus (4) 4
cancer therapies (3) 3
chromatography (3) 3
liquid chromatography (3) 3
metabolism (3) 3
metabolites (3) 3
oncology (3) 3
cancer (2) 2
drug dosages (2) 2
formic acid (2) 2
gene expression (2) 2
genomics (2) 2
hematology (2) 2
in-vitro (2) 2
liver (2) 2
liver cancer (2) 2
mass spectrometry (2) 2
mathematical analysis (2) 2
medicine (2) 2
metabolic networks and pathways (2) 2
multidisciplinary sciences (2) 2
pharmacokinetics (2) 2
pharmacology (2) 2
pharmacy (2) 2
plasma (2) 2
research article (2) 2
science (2) 2
tandem mass spectrometry - methods (2) 2
tumors (2) 2
17-dihydroexemestane (1) 1
a549 cells (1) 1
acetonitrile (1) 1
acids (1) 1
adjuvant therapy (1) 1
analysis (1) 1
androstadienes - blood (1) 1
androstadienes - pharmacokinetics (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - metabolism (1) 1
antineoplastic agents - pharmacokinetics (1) 1
antineoplastic agents - toxicity (1) 1
antineoplastic combined chemotherapy protocols - pharmacology (1) 1
antioxidants - analysis (1) 1
antioxidants - pharmacokinetics (1) 1
apoptosis (1) 1
apoptosis - drug effects (1) 1
aromatase inhibitors (1) 1
belinostat (1) 1
bh3 interacting domain death agonist protein - agonists (1) 1
bh3 interacting domain death agonist protein - metabolism (1) 1
biochemical research methods (1) 1
biology (1) 1
blood plasma (1) 1
breast cancer (1) 1
cancer patients (1) 1
carboplatin (1) 1
carcinoma, hepatocellular - enzymology (1) 1
carcinoma, hepatocellular - genetics (1) 1
carcinoma, hepatocellular - metabolism (1) 1
carcinoma, non-small-cell lung - drug therapy (1) 1
carcinoma, non-small-cell lung - genetics (1) 1
carcinoma, non-small-cell lung - metabolism (1) 1
carcinoma, non-small-cell lung - pathology (1) 1
care and treatment (1) 1
caspase 3 - metabolism (1) 1
caspase 8 - metabolism (1) 1
caspase inhibitors - pharmacology (1) 1
caspase-8 activation (1) 1
cell culture (1) 1
cell cycle (1) 1
cell proliferation - drug effects (1) 1
chemistry, analytical (1) 1
chromatography, high pressure liquid - methods (1) 1
chromatography, liquid - methods (1) 1
clinical genetics (1) 1
clinical trials (1) 1
coefficient of variation (1) 1
correction (1) 1
cyclin-dependent kinases (1) 1
death (1) 1
dependent kinase inhibitor (1) 1
digestive system (1) 1
dose-response relationship, drug (1) 1
drug discovery (1) 1
drug information (1) 1
drug metabolism (1) 1
drug research and development (1) 1
drug stability (1) 1
drugs and devices (1) 1
dynamic tests (1) 1
efficacy (1) 1
elution (1) 1
enhancement (1) 1
enzymes (1) 1
epigenetics (1) 1
ergothioneine - analysis (1) 1
ergothioneine - blood (1) 1
ergothioneine - pharmacokinetics (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e54522
Belinostat is a hydroxamate class HDAC inhibitor that has demonstrated activity in peripheral T-cell lymphoma and is undergoing clinical trials for... 
HISTONE DEACETYLASE INHIBITOR | IN-VITRO | MULTIDISCIPLINARY SCIENCES | GENE-EXPRESSION | PHASE-II | T-CELL LYMPHOMA | OVARIAN-CANCER | IDENTIFICATION | UGT1A1-ASTERISK-28 GENOTYPE | TUMORS | VORINOSTAT | Humans | Microsomes, Liver - metabolism | Substrate Specificity | Antineoplastic Agents - toxicity | Antineoplastic Agents - metabolism | Glucuronosyltransferase - genetics | Histone Deacetylase Inhibitors - pharmacokinetics | Carcinoma, Hepatocellular - genetics | Antineoplastic Agents - pharmacokinetics | Liver Neoplasms - enzymology | Hydroxamic Acids - toxicity | Gene Expression | Liver Neoplasms - genetics | Drug Stability | Metabolome | Genotype | Carcinoma, Hepatocellular - enzymology | Sulfonamides - pharmacokinetics | Hydroxamic Acids - pharmacokinetics | Hydroxamic Acids - metabolism | Glucuronosyltransferase - metabolism | Metabolic Networks and Pathways | Histone Deacetylase Inhibitors - toxicity | Liver Neoplasms - metabolism | Sulfonamides - metabolism | Sulfonamides - toxicity | Kinetics | Histone Deacetylase Inhibitors - metabolism | Carcinoma, Hepatocellular - metabolism | Hydrogen-Ion Concentration | Antimitotic agents | Medical research | Liver cancer | Enzymes | Cancer patients | Care and treatment | Metabolites | Physiological aspects | Medicine, Experimental | Non-Hodgkin's lymphomas | Antineoplastic agents | T cells | Histone deacetylase | Liver | Genomics | Clinical trials | Science | Oncology | Hepatocellular carcinoma | Lymphocytes T | Cancer therapies | Genotype & phenotype | Drug dosages | Neutropenia | Hematology | Pharmacology | FDA approval | Metabolism | Patients | Lymphoma | Substrates | Microsomes | Chromatography | Acids | Pharmacy | Epigenetics | Lymphomas | Pharmacokinetics | T-cell lymphoma | Cancer
Journal Article
Cancer Letters, ISSN 0304-3835, 2016, Volume 381, Issue 1, pp. 49 - 57
Highlights • Seliciclib® augmented anticancer effects of Belinostat® in NSCLC cells • Increase in cellular apoptosis was observed with combined therapy •... 
Hematology, Oncology and Palliative Medicine | Caspase-8 activation | Seliciclib | Belinostat | Non-small cell lung cancer | Truncated BID | CARBOPLATIN | ROSCOVITINE | DEATH | DEPENDENT KINASE INHIBITOR | P53 | PACLITAXEL | Seliciclib (R) | ONCOLOGY | ENHANCEMENT | HISTONE DEACETYLASE INHIBITORS | EXPRESSION | Belinostat (R) | FLAVOPIRIDOL | Lung Neoplasms - drug therapy | Caspase Inhibitors - pharmacology | Apoptosis - drug effects | Humans | Lung Neoplasms - metabolism | Caspase 3 - metabolism | Caspase 8 - metabolism | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | Lung Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Transfection | RNA Interference | Time Factors | Inhibitory Concentration 50 | Hydroxamic Acids - pharmacology | BH3 Interacting Domain Death Agonist Protein - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | A549 Cells | Carcinoma, Non-Small-Cell Lung - genetics | Purines - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Tumor Suppressor Protein p53 - metabolism | Sulfonamides - pharmacology | Poly(ADP-ribose) Polymerases - metabolism | Signal Transduction - drug effects | X-Linked Inhibitor of Apoptosis Protein - metabolism | Histone Deacetylase Inhibitors - pharmacology | BH3 Interacting Domain Death Agonist Protein - agonists | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Flow cytometry | Cell culture | Substance abuse treatment | Immunoglobulins | Cyclin-dependent kinases | Mortality | Lung cancer | Kinases | Gene expression | Experiments | Cancer therapies | Studies | Proteins | Cell cycle | Standard deviation | Drug dosages | Tumors | Apoptosis
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.